This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMaven Brands（TLA）株式概要Together with its subsidiary, engages in the production, toll-processing, and packaging of medical cannabis in Canada. 詳細TLA ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬当社が推定した公正価値より55.9%で取引されている リスク分析意味のある時価総額がありません ( €481K )収益が 100 万ドル未満 ( CA$0 )マイナスの株主資本 株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るTLA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,735 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG489,735 investors already sharing narrativesYour Fair Value€Current Price€0.0005該当なし内在価値ディスカウントEst. Revenue$PastFuture-16m2m2016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesMaven Brands Inc. 競合他社TFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.4mbioXXmedSymbol: XTRA:T5O0Market cap: €329.8kCantourage GroupSymbol: XTRA:HIGHMarket cap: €66.6m価格と性能株価の高値、安値、推移の概要Maven Brands過去の株価現在の株価CA$0.000552週高値CA$0.02752週安値CA$0.0005ベータ2.581ヶ月の変化0%3ヶ月変化0%1年変化0%3年間の変化-99.82%5年間の変化-99.98%IPOからの変化-99.93%最新ニュースBuying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.最新情報をもっと見るRecent updatesBuying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jun 17Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 69%. The fair value is estimated to be €0.008, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • May 29Now 34% undervaluedOver the last 90 days, the stock is up 400%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Apr 26Now 21% undervaluedOver the last 90 days, the stock is up 2,500%. The fair value is estimated to be €0.016, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Apr 05Now 24% undervaluedOver the last 90 days, the stock is up 1,000%. The fair value is estimated to be €0.0073, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Mar 09Now 35% undervalued after recent price dropOver the last 90 days, the stock is down 50%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 170% over the last 3 years. Earnings per share has grown by 80%.お知らせ • Nov 22Maven Brands Inc., Annual General Meeting, Jan 31, 2023Maven Brands Inc., Annual General Meeting, Jan 31, 2023.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Feb 19Founder & Director recently sold €153k worth of stockOn the 17th of February, Darcy Bomford sold around 339k shares on-market at roughly €0.45 per share. This was the largest sale by an insider in the last 3 months. This was Darcy's only on-market trade for the last 12 months.株主還元TLADE PharmaceuticalsDE 市場7D0%-2.8%-0.4%1Y0%40.9%-0.8%株主還元を見る業界別リターン: TLA過去 1 年間で40.9 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: TLAは、過去 1 年間で-0.8 % のリターンを上げたGerman市場を下回りました。価格変動Is TLA's price volatile compared to industry and market?TLA volatilityTLA Average Weekly Movementn/aPharmaceuticals Industry Average Movement6.0%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.8%安定した株価: TLAの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のTLAのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2013n/aDarcy Bomfordmavenbrands.caもっと見るMaven Brands Inc. 基礎のまとめMaven Brands の収益と売上を時価総額と比較するとどうか。TLA 基礎統計学時価総額€480.67k収益（TTM）-€518.16k売上高(TTM)n/a0.0xP/Sレシオ-0.9xPER（株価収益率TLA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TLA 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$757.63k収益-CA$757.63k直近の収益報告Dec 31, 2022次回決算日該当なし一株当たり利益（EPS）-0.022グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-341.6%TLA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/07 19:13終値2023/10/10 00:00収益2022/12/31年間収益2022/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Maven Brands Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Buying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jun 17Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 69%. The fair value is estimated to be €0.008, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • May 29Now 34% undervaluedOver the last 90 days, the stock is up 400%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Apr 26Now 21% undervaluedOver the last 90 days, the stock is up 2,500%. The fair value is estimated to be €0.016, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Apr 05Now 24% undervaluedOver the last 90 days, the stock is up 1,000%. The fair value is estimated to be €0.0073, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Mar 09Now 35% undervalued after recent price dropOver the last 90 days, the stock is down 50%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 170% over the last 3 years. Earnings per share has grown by 80%.
お知らせ • Nov 22Maven Brands Inc., Annual General Meeting, Jan 31, 2023Maven Brands Inc., Annual General Meeting, Jan 31, 2023.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Feb 19Founder & Director recently sold €153k worth of stockOn the 17th of February, Darcy Bomford sold around 339k shares on-market at roughly €0.45 per share. This was the largest sale by an insider in the last 3 months. This was Darcy's only on-market trade for the last 12 months.
